Results 171 to 180 of about 6,421 (186)

Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label phase 3b study

Lancet, The, 2014
Bonaventura Clotet, Judith Feinberg, Andrea Antinori   +2 more
exaly  

Nirmatrelvir+ritonavir/tacrolimus interaction

Reactions Weekly, 2022
openaire   +1 more source

A Preliminary Study of Ritonavir, an Inhibitor of HIV-1 Protease, to Treat HIV-1 Infection

New England Journal of Medicine, 1995
William G Powderly
exaly  

Esomeprazole/nirmatrelvir+ritonavir/tozinameran

Reactions Weekly, 2023
openaire   +1 more source

A Short-Term Study of the Safety, Pharmacokinetics, and Efficacy of Ritonavir, an Inhibitor of HIV-1 Protease

New England Journal of Medicine, 1995
Emilio Bouza, Rafael Delgado
exaly  

Nirmatrelvir+ritonavir/phenylephrine/verapamil

Reactions Weekly, 2023
openaire   +1 more source

Extended pre-exposure prophylaxis with lopinavir–ritonavir versus lamivudine to prevent HIV-1 transmission through breastfeeding up to 50 weeks in infants in Africa (ANRS 12174): a randomised controlled trial

Lancet, The, 2016
Nicolas Nagot, Roselyne Vallo, Grace Ndeezi   +2 more
exaly  

Bebtelovimab/nirmatrelvir+ritonavir/remdesivir

Reactions Weekly, 2023
openaire   +1 more source

Fatal interaction between ritonavir and MDMA

Lancet, The, 1998
exaly  

Nirmatrelvir/Ritonavir/Remdesivir

Reactions Weekly
openaire   +1 more source